Jiangsu Hengrui Medicine Co. Ltd. Issues Patent for Anti-Claudin 18.2 Antibody

Strategic Insights -

Chinese pharmaceutical company Jiangsu Hengrui Medicine Co. Ltd. has been issued a patent for an anti-Claudin 18.2 antibody by the United States Patent and Trademark Office. The patent, filed on March 31, 2020, was published online on September 30, 2025, under the patent number 12428478. The inventors of the patent, Ge Hu, Tao Weikang, and Yang Yang, have developed an anti-Claudin 18.2 antibody that targets a protein associated with gastric cancer and other types of cancer.

The anti-Claudin 18.2 antibody is part of a new class of cancer treatments that target specific proteins on the surface of cancer cells. The patent describes several embodiments of the antibody, including its heavy chain and light chain variable regions, as well as its heavy chain and light chain constant regions. The claims of the patent cover a wide range of applications for the anti-Claudin 18.2 antibody, including its use in the treatment of various types of cancer.

Key Takeaways:

  • The patent, filed on March 31, 2020, was published online on September 30, 2025, under the patent number 12428478.
  • The anti-Claudin 18.2 antibody is a novel therapy for gastric cancer and other types of cancer.
  • The antibody targets the Claudin 18.2 protein, which is associated with the proliferation and metastasis of cancer cells.
  • The patent describes several embodiments of the antibody, including its heavy chain and light chain variable regions, as well as its heavy chain and light chain constant regions.
  • The claims of the patent cover a wide range of applications for the anti-Claudin 18.2 antibody, including its use in the treatment of head and neck squamous cell cancer, lung cancer, breast cancer, and other types of cancer.

Statistics:

  • 15 claims are covered in the patent, describing the anti-Claudin 18.2 antibody and its applications in cancer treatment.
  • The patent number 12428478 was issued on September 30, 2025.
  • The filing date of the patent was March 31, 2020.
  • The antibody targets the Claudin 18.2 protein, which is expressed on the surface of cancer cells.
  • Gastric cancer is the primary indication for the anti-Claudin 18.2 antibody, but the patent also covers other types of cancer, including lung, breast, and colon cancer.

Sources:

  • Ge, Hu. Anti-Claudin 18.2 antibody and application thereof. U.S. Patent Number 12428478, filed March 31, 2020, and published online on September 30, 2025. Patent URL (for desktop use only): https://ppubs.uspto.gov/pubwebapp/external.html?q=(12428478)&db=USPAT&type=ids
  • NewsRx LLC. Jiangsu Hengrui Medicine Co. Ltd. Issues Patent for Anti-Claudin 18.2 Antibody. September 30, 2025.